MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1

L. Venturutti, R. I. Cordo Russo, M. A. Rivas, M. F. Mercogliano, F. Izzo, R. H. Oakley, M. G. Pereyra, M. de Martino, C. J. Proietti, P. Yankilevich, J. C. Roa, P. Guzmán, E. Cortese, D. H. Allemand, Hui-ming Huang, E. H. Charreau, J. A. Cidlowski, R. Schillaci, P. V. Elizalde

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

ErbB-2 amplification/overexpression accounts for an aggressive breast cancer (BC) subtype (ErbB-2-positive). Enhanced ErbB-2 expression was also found in gastric cancer (GC) and has been correlated with poor clinical outcome. The ErbB-2-targeted therapies trastuzumab (TZ), a monoclonal antibody, and lapatinib, a tyrosine kinase inhibitor, have proved highly beneficial. However, resistance to such therapies remains a major clinical challenge. We here revealed a novel mechanism underlying the antiproliferative effects of both agents in ErbB-2-positive BC and GC. TZ and lapatinib ability to block extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase (PI3K)/AKT in sensitive cells inhibits c-Myc activation, which results in upregulation of miR-16. Forced expression of miR-16 inhibited in vitro proliferation in BC and GC cells, both sensitive and resistant to TZ and lapatinib, as well as in a preclinical BC model resistant to these agents. This reveals miR-16 role as tumor suppressor in ErbB-2-positive BC and GC. Using genome-wide expression studies and miRNA target prediction algorithms, we identified cyclin J and far upstream element-binding protein 1 (FUBP1) as novel miR-16 targets, which mediate miR-16 antiproliferative effects. Supporting the clinical relevance of our results, we found that high levels of miR-16 and low or null FUBP1 expression correlate with TZ response in ErbB-2-positive primary BCs. These findings highlight a potential role of miR-16 and FUBP1 as biomarkers of sensitivity to TZ therapy. Furthermore, we revealed miR-16 as an innovative therapeutic agent for TZ- and lapatinib-resistant ErbB-2-positive BC and GC.Oncogene advance online publication, 9 May 2016; doi:10.1038/onc.2016.151.

Original languageEnglish (US)
JournalOncogene
DOIs
StateAccepted/In press - May 9 2016

Fingerprint

Stomach Neoplasms
Carrier Proteins
Breast Neoplasms
Phosphatidylinositol 3-Kinase
Trastuzumab
lapatinib
Cyclins
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Therapeutics
MicroRNAs
Oncogenes
Protein-Tyrosine Kinases
Publications
Up-Regulation
Biomarkers
Monoclonal Antibodies
Genome
Neoplasms

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Venturutti, L., Cordo Russo, R. I., Rivas, M. A., Mercogliano, M. F., Izzo, F., Oakley, R. H., ... Elizalde, P. V. (Accepted/In press). MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. Oncogene. https://doi.org/10.1038/onc.2016.151

MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. / Venturutti, L.; Cordo Russo, R. I.; Rivas, M. A.; Mercogliano, M. F.; Izzo, F.; Oakley, R. H.; Pereyra, M. G.; de Martino, M.; Proietti, C. J.; Yankilevich, P.; Roa, J. C.; Guzmán, P.; Cortese, E.; Allemand, D. H.; Huang, Hui-ming; Charreau, E. H.; Cidlowski, J. A.; Schillaci, R.; Elizalde, P. V.

In: Oncogene, 09.05.2016.

Research output: Contribution to journalArticle

Venturutti, L, Cordo Russo, RI, Rivas, MA, Mercogliano, MF, Izzo, F, Oakley, RH, Pereyra, MG, de Martino, M, Proietti, CJ, Yankilevich, P, Roa, JC, Guzmán, P, Cortese, E, Allemand, DH, Huang, H, Charreau, EH, Cidlowski, JA, Schillaci, R & Elizalde, PV 2016, 'MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1', Oncogene. https://doi.org/10.1038/onc.2016.151
Venturutti, L. ; Cordo Russo, R. I. ; Rivas, M. A. ; Mercogliano, M. F. ; Izzo, F. ; Oakley, R. H. ; Pereyra, M. G. ; de Martino, M. ; Proietti, C. J. ; Yankilevich, P. ; Roa, J. C. ; Guzmán, P. ; Cortese, E. ; Allemand, D. H. ; Huang, Hui-ming ; Charreau, E. H. ; Cidlowski, J. A. ; Schillaci, R. ; Elizalde, P. V. / MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. In: Oncogene. 2016.
@article{104538532d21460fae748c2c16458f50,
title = "MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1",
abstract = "ErbB-2 amplification/overexpression accounts for an aggressive breast cancer (BC) subtype (ErbB-2-positive). Enhanced ErbB-2 expression was also found in gastric cancer (GC) and has been correlated with poor clinical outcome. The ErbB-2-targeted therapies trastuzumab (TZ), a monoclonal antibody, and lapatinib, a tyrosine kinase inhibitor, have proved highly beneficial. However, resistance to such therapies remains a major clinical challenge. We here revealed a novel mechanism underlying the antiproliferative effects of both agents in ErbB-2-positive BC and GC. TZ and lapatinib ability to block extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase (PI3K)/AKT in sensitive cells inhibits c-Myc activation, which results in upregulation of miR-16. Forced expression of miR-16 inhibited in vitro proliferation in BC and GC cells, both sensitive and resistant to TZ and lapatinib, as well as in a preclinical BC model resistant to these agents. This reveals miR-16 role as tumor suppressor in ErbB-2-positive BC and GC. Using genome-wide expression studies and miRNA target prediction algorithms, we identified cyclin J and far upstream element-binding protein 1 (FUBP1) as novel miR-16 targets, which mediate miR-16 antiproliferative effects. Supporting the clinical relevance of our results, we found that high levels of miR-16 and low or null FUBP1 expression correlate with TZ response in ErbB-2-positive primary BCs. These findings highlight a potential role of miR-16 and FUBP1 as biomarkers of sensitivity to TZ therapy. Furthermore, we revealed miR-16 as an innovative therapeutic agent for TZ- and lapatinib-resistant ErbB-2-positive BC and GC.Oncogene advance online publication, 9 May 2016; doi:10.1038/onc.2016.151.",
author = "L. Venturutti and {Cordo Russo}, {R. I.} and Rivas, {M. A.} and Mercogliano, {M. F.} and F. Izzo and Oakley, {R. H.} and Pereyra, {M. G.} and {de Martino}, M. and Proietti, {C. J.} and P. Yankilevich and Roa, {J. C.} and P. Guzm{\'a}n and E. Cortese and Allemand, {D. H.} and Hui-ming Huang and Charreau, {E. H.} and Cidlowski, {J. A.} and R. Schillaci and Elizalde, {P. V.}",
year = "2016",
month = "5",
day = "9",
doi = "10.1038/onc.2016.151",
language = "English (US)",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1

AU - Venturutti, L.

AU - Cordo Russo, R. I.

AU - Rivas, M. A.

AU - Mercogliano, M. F.

AU - Izzo, F.

AU - Oakley, R. H.

AU - Pereyra, M. G.

AU - de Martino, M.

AU - Proietti, C. J.

AU - Yankilevich, P.

AU - Roa, J. C.

AU - Guzmán, P.

AU - Cortese, E.

AU - Allemand, D. H.

AU - Huang, Hui-ming

AU - Charreau, E. H.

AU - Cidlowski, J. A.

AU - Schillaci, R.

AU - Elizalde, P. V.

PY - 2016/5/9

Y1 - 2016/5/9

N2 - ErbB-2 amplification/overexpression accounts for an aggressive breast cancer (BC) subtype (ErbB-2-positive). Enhanced ErbB-2 expression was also found in gastric cancer (GC) and has been correlated with poor clinical outcome. The ErbB-2-targeted therapies trastuzumab (TZ), a monoclonal antibody, and lapatinib, a tyrosine kinase inhibitor, have proved highly beneficial. However, resistance to such therapies remains a major clinical challenge. We here revealed a novel mechanism underlying the antiproliferative effects of both agents in ErbB-2-positive BC and GC. TZ and lapatinib ability to block extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase (PI3K)/AKT in sensitive cells inhibits c-Myc activation, which results in upregulation of miR-16. Forced expression of miR-16 inhibited in vitro proliferation in BC and GC cells, both sensitive and resistant to TZ and lapatinib, as well as in a preclinical BC model resistant to these agents. This reveals miR-16 role as tumor suppressor in ErbB-2-positive BC and GC. Using genome-wide expression studies and miRNA target prediction algorithms, we identified cyclin J and far upstream element-binding protein 1 (FUBP1) as novel miR-16 targets, which mediate miR-16 antiproliferative effects. Supporting the clinical relevance of our results, we found that high levels of miR-16 and low or null FUBP1 expression correlate with TZ response in ErbB-2-positive primary BCs. These findings highlight a potential role of miR-16 and FUBP1 as biomarkers of sensitivity to TZ therapy. Furthermore, we revealed miR-16 as an innovative therapeutic agent for TZ- and lapatinib-resistant ErbB-2-positive BC and GC.Oncogene advance online publication, 9 May 2016; doi:10.1038/onc.2016.151.

AB - ErbB-2 amplification/overexpression accounts for an aggressive breast cancer (BC) subtype (ErbB-2-positive). Enhanced ErbB-2 expression was also found in gastric cancer (GC) and has been correlated with poor clinical outcome. The ErbB-2-targeted therapies trastuzumab (TZ), a monoclonal antibody, and lapatinib, a tyrosine kinase inhibitor, have proved highly beneficial. However, resistance to such therapies remains a major clinical challenge. We here revealed a novel mechanism underlying the antiproliferative effects of both agents in ErbB-2-positive BC and GC. TZ and lapatinib ability to block extracellular signal-regulated kinases 1/2 and phosphatidylinositol-3 kinase (PI3K)/AKT in sensitive cells inhibits c-Myc activation, which results in upregulation of miR-16. Forced expression of miR-16 inhibited in vitro proliferation in BC and GC cells, both sensitive and resistant to TZ and lapatinib, as well as in a preclinical BC model resistant to these agents. This reveals miR-16 role as tumor suppressor in ErbB-2-positive BC and GC. Using genome-wide expression studies and miRNA target prediction algorithms, we identified cyclin J and far upstream element-binding protein 1 (FUBP1) as novel miR-16 targets, which mediate miR-16 antiproliferative effects. Supporting the clinical relevance of our results, we found that high levels of miR-16 and low or null FUBP1 expression correlate with TZ response in ErbB-2-positive primary BCs. These findings highlight a potential role of miR-16 and FUBP1 as biomarkers of sensitivity to TZ therapy. Furthermore, we revealed miR-16 as an innovative therapeutic agent for TZ- and lapatinib-resistant ErbB-2-positive BC and GC.Oncogene advance online publication, 9 May 2016; doi:10.1038/onc.2016.151.

UR - http://www.scopus.com/inward/record.url?scp=84966477980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966477980&partnerID=8YFLogxK

U2 - 10.1038/onc.2016.151

DO - 10.1038/onc.2016.151

M3 - Article

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -